Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing

Company Overview - Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for genetically defined muscle diseases, utilizing its FORCE platform to address unmet medical needs in rare neuromuscular disorders [6][8] - The company targets patients with rare muscle disorders and associated healthcare providers, primarily in the U.S. biopharmaceutical and rare disease markets [8] Financial Metrics - As of February 17, 2026, Dyne Therapeutics' stock price was $15.28, with a market capitalization of $2.50 billion [4] - The company reported a net income of ($423.80 million) for the trailing twelve months (TTM) [4] - The one-year price change for Dyne Therapeutics was 10.89%, which underperformed the S&P 500 by 2.07 percentage points [3][4] Recent Developments - Palo Alto Investors LP disclosed an increase of 209,523 shares in Dyne Therapeutics, valued at an estimated $3.97 million based on quarterly average pricing [1][2] - This acquisition raised Palo Alto Investors' stake in Dyne Therapeutics to 4.01% of its reported 13F assets under management (AUM) [3] - The fund's quarter-end position in Dyne Therapeutics increased in value by $12.82 million, accounting for both additional shares and price appreciation [2]